Regeneron Pharmaceuticals Inc (REGN) : March Altus Capital Management Lp reduced its stake in Regeneron Pharmaceuticals Inc by 21.43% during the most recent quarter end. The investment management company now holds a total of 2,291 shares of Regeneron Pharmaceuticals Inc which is valued at $846,433 after selling 625 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on May 12, 2016.Regeneron Pharmaceuticals Inc makes up approximately 8.52% of March Altus Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Ipswich Investment Management reduced its stake in REGN by selling 400 shares or 72.73% in the most recent quarter. The Hedge Fund company now holds 150 shares of REGN which is valued at $55,419. Regeneron Pharmaceuticals Inc makes up approx 0.03% of Ipswich Investment Management’s portfolio.Blackrock Fund Advisors boosted its stake in REGN in the latest quarter, The investment management firm added 113,864 additional shares and now holds a total of 2,208,677 shares of Regeneron Pharmaceuticals Inc which is valued at $816 Million. Regeneron Pharmaceuticals Inc makes up approx 0.19% of Blackrock Fund Advisors’s portfolio.Mutual Of America Capital Management boosted its stake in REGN in the latest quarter, The investment management firm added 244 additional shares and now holds a total of 8,901 shares of Regeneron Pharmaceuticals Inc which is valued at $3.3 Million. Regeneron Pharmaceuticals Inc makes up approx 0.07% of Mutual Of America Capital Management’s portfolio.
Regeneron Pharmaceuticals Inc opened for trading at $383.37 and hit $388 on the upside on Friday, eventually ending the session at $386, with a gain of 0.70% or 2.7 points. The heightened volatility saw the trading volume jump to 7,94,990 shares. Company has a market cap of $39,821,690 M.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.55. The company had revenue of $1201.00 million for the quarter, compared to analysts expectations of $1178.39 million. The company’s revenue was up 38.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.88 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.